Astrazeneca Pharma Peer Comparison
NSE: ASTRAZEN | BSE: 506820
₹6,133.50
As on 18-Nov-2026 14:14IST
Market cap
₹15,628 Cr
Revenue (TTM)
₹2,602 Cr
P/E Ratio
87.9
P/B Ratio
17.8
Div. Yield
0.6 %
| Astrazeneca Pharma | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
15,628 | 18,172 | 18,911 | 15,875 | 17,389 |
Revenue (₹ Cr) |
2,602 | 1,842 | 3,330 | 2,383 | 2,654 |
Net Profit (₹ Cr) |
177.73 | 308.62 | 720.77 | 700.18 | 859.38 |
Net Margin (%) |
6.74 | 16.63 | 21.60 | 27.87 | 30.42 |
RoE (%) |
21.49 | 11.81 | 18.93 | 18.40 | 18.58 |
Price to Earnings |
87.93 | 54.66 | 26.73 | 23.04 | 20.23 |
Price-To-Book |
17.78 | 6.59 | 4.56 | 4.07 | 3.97 |
Income Statement (₹ Cr)
| Astrazeneca Pharma | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2,602.07 | 1,841.62 | 3,329.63 | 2,383.13 | 2,654.29 |
|
Total Income
|
2,637.50 | 1,855.87 | 3,337.47 | 2,512.01 | 2,825.39 |
|
Total Expenditure
|
2,351.82 | 1,328.95 | 2,168.88 | 1,552.50 | 1,681.39 |
|
EBITDA
|
250.25 | 512.67 | 1,160.75 | 830.63 | 972.90 |
|
Depreciation
|
20.02 | 130.47 | 285.40 | 83.19 | 57.71 |
|
EBIT
|
230.23 | 382.20 | 875.35 | 747.44 | 915.19 |
|
Interest
|
6.94 | 49.12 | 187.51 | 0.94 | 8.91 |
|
Other Income
|
35.43 | 14.25 | 7.84 | 128.88 | 171.10 |
|
Exceptional Items
|
-14.80 | 11.73 | -53.14 | 0.00 | 82.90 |
|
Profit before Tax
|
243.92 | 359.06 | 642.54 | 875.38 | 1,160.28 |
|
Provision for Tax
|
66.19 | 50.44 | -78.23 | 175.20 | 300.90 |
|
Profit after Tax
|
177.73 | 308.62 | 720.77 | 700.18 | 859.38 |
Liabilities (₹ Cr)
| Astrazeneca Pharma | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
878.92 | 2,757.68 | 4,144.34 | 3,902.45 | 4,385.41 |
|
Minority Interest
|
0.00 | 0.00 | -10.85 | -11.18 | 0.00 |
|
Non-Current Liabilities
|
122.97 | 363.37 | 758.48 | 55.61 | 222.21 |
|
Current Liabilities
|
1,189.51 | 1,016.50 | 2,681.14 | 366.06 | 685.36 |
|
Total Liabilities
|
2,414.58 | 3,705.61 | 7,246.72 | 4,037.51 | 4,921.88 |
Assets (₹ Cr)
| Astrazeneca Pharma | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
53.64 | 2,763.86 | 5,578.78 | 1,528.69 | 905.21 |
|
Current Assets
|
1,936.62 | 1,277.15 | 1,800.86 | 2,696.84 | 4,024.56 |
|
Total Assets
|
2,414.58 | 3,705.61 | 7,246.72 | 4,037.51 | 4,921.88 |
|
Total Debt*
|
0.00 | 657.97 | 2,309.68 | 0.57 | 2.50 |
|
Net Current Assets
|
747.11 | 260.65 | -880.28 | 2,330.78 | 3,339.20 |
|
Contingent Liabilities
|
121.23 | 160.01 | 51.57 | 17.53 | 370.49 |
Cashflow (₹ Cr)
| Astrazeneca Pharma | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-15.14 | 342.18 | 537.99 | 523.24 | 967.57 |
|
Cash Flow from Investing Activities
|
18.69 | -325.92 | -369.46 | -582.30 | -561.67 |
|
Cash from Financing Activities
|
-91.97 | 13.62 | -313.53 | -46.46 | -798.31 |
|
Net Cash Inflow / Outflow
|
-88.42 | 29.88 | -145.00 | -105.52 | -392.41 |
Ratios
Profitability Ratios
| Astrazeneca Pharma | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
ROCE (%)
|
31.24 | 11.43 | 14.47 | 24.97 | 23.39 |
|
ROE (%)
|
21.49 | 11.81 | 18.93 | 18.40 | 18.58 |
|
ROA (%)
|
9.34 | 8.09 | 9.78 | 17.77 | 17.36 |
|
EBIT Margin (%)
|
8.85 | 20.75 | 26.29 | 31.36 | 34.48 |
|
Net Margin (%)
|
6.74 | 16.63 | 21.60 | 27.87 | 30.42 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Astrazeneca Pharma | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
29.70 | 37.26 | 11.06 | 16.84 | 11.75 |
|
EBIT Growth (%)
|
-15.90 | 56.89 | 13.71 | 18.76 | 21.45 |
|
Net Profit Growth (%)
|
-10.76 | 127.86 | 60.98 | 17.44 | 2.39 |
|
EPS Growth (%)
|
-18.93 | 5.65 | 80.38 | 17.02 | 13.17 |
|
Book Value Growth (%)
|
13.51 | 9.67 | 36.71 | 26.75 | -0.34 |
Valuation Ratios
| Astrazeneca Pharma | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Price / Earnings
|
81.89 | 56.81 | 24.70 | 24.83 | 21.87 |
|
Price / Book Value
|
17.54 | 6.50 | 4.55 | 4.38 | 3.98 |
|
Dividend Yield (%)
|
0.58 | 0.07 | 0.00 | 0.36 | 1.97 |
|
EV/EBITDA
|
59.81 | 36.18 | 18.19 | 19.39 | 14.74 |
|
Market Cap (₹ Cr)
|
19,398.64 | 6,819.66 | 17,980.08 | 11,439.22 | 21,592.90 |
Solvency Ratios
| Astrazeneca Pharma | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.08 | 0.10 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
-- | 0.16 | 0.12 | 0.00 | 0.00 |
|
Current Ratio
|
1.63 | 1.26 | 0.67 | 7.37 | 5.87 |
|
Quick Ratio
|
0.76 | 0.82 | 0.49 | 5.88 | 5.23 |
|
Interest Coverage
|
36.15 | 8.31 | 4.43 | 932.26 | 131.22 |
Operating Efficiency Ratios
| Astrazeneca Pharma | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
10.95 | 29.09 | 18.98 | 37.32 | 9.10 |
|
Asset Turnover
|
1.37 | 0.48 | 0.45 | 0.60 | 0.54 |
|
Receivable days
|
31.88 | 113.81 | 63.88 | 121.68 | 26.06 |
|
Inventory Days
|
126.03 | 84.76 | 43.27 | 63.83 | 65.95 |
|
Payable days
|
163.79 | 101.94 | 151.85 | 108.28 | 81.01 |
|
Cash Conversion Cycle
|
-5.88 | 96.62 | -44.70 | 77.23 | 11.00 |